Kymera Therapeutics

We’re at the 7th Annual #TPD & Induced Proximity Summit in #Boston this week! Stop by our presentations, including plenary sessions with Nello Mainolfi, Juliet Williams, and Xiao (Sean) Zhu where they’ll discuss key milestones in the field and how Kymera is working to reinvent the treatment of human disease with our first-in-class small molecule degrader medicines. #ReinventingMedicine #TPDSummitBoston2024 

We have been barrier breakers in our quest to target #STAT6. KT-621, our STAT6 degrader, has the potential to provide biologics-like activity with an oral small molecule profile for numerous #Th2 driven immuno-inflammatory diseases, and we’re thrilled to be the first company to advance a program like this into the clinic. This is just the beginning as we work to revolutionize disease treatment and find solutions for patients. Hear from our CEO Nello Mainolfi as he discusses the origin and opportunity of this milestone moment and what it means for patients! #RevolutionizingImmunology

Don’t miss Qi (Amy) Wang presenting today at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting on KT-621, our first-in-class oral STAT6 degrader with the potential to address multiple immuno-inflammatory diseases. Check out our poster: https://bit.ly/4eS3Aqa #ACAAI24 #RevolutionizingImmunology 

We are pleased to announce that we've initiated dosing in the Phase 1 clinical trial of KT-621, our investigational, first-in-class, oral #STAT6 degrader for immuno-inflammatory diseases. Read the full announcement on this exciting milestone here: https://bit.ly/3NHzppy #RevolutionizingImmunology #TH2 #DrugDevelopment

#SaveTheDate! Join us on October 31st for our quarterly financial results and latest company updates: https://bit.ly/3NCipRG

This week at the EORTC-NCI-AACR Symposium, we’re presenting three scientific posters showcasing our innovative #TPD platform. Learn more: https://bit.ly/3NzbEjA #ENASymp24 #ReinventingMedicine 

“Our goal has always been to go after targets that have not been drugged before by marketed products, where protein degradation would provide a technical solution to unlocking new target biology.” Check out this recent news article in Nature Portfolio featuring our CEO Nello Mainolfi discussing how #TPD can unlock previously intractable disease targets, including our STAT6 and IRAK4 degraders in immunology: https://bit.ly/4f8IRyd #DrugDiscovery #Biotech #Pioneer #ReinventingMedicine

We are thrilled that the FDA has cleared our IND application for our first-in-class oral STAT6 degrader, KT-621. As the first #TPD company to advance a degrader for #immunology into clinical trials, this exciting milestone highlights our commitment to delivering potentially differentiated solutions for patients suffering from immuno-inflammatory diseases, and we could not have accomplished this without the hard work of our amazing team. Read the full press release: https://bit.ly/47Y32wo #RevolutionizingImmunology  

Congratulations to our CMO, Jared Gollob, for being recognized as part of the PharmaVoice 100 most innovative and impactful individuals in the #lifescience industry! We’re inspired by Jared’s leadership and vision as we continue to advance a new class of transformative medicines for patients. Learn more: https://bit.ly/3BCeJwJ #PharmaVoice100 #Leadership #Biotech #ReinventingMedicine

We’re working to revolutionize the treatment of immuno-inflammatory diseases by building an industry-leading #immunology pipeline of oral degrader medicines. Check out our presentation at the European Academy of Dermatology and Venereology 2024 Congress highlighting new preclinical data on KT-621, our first-in-class, oral #STAT6 degrader: https://bit.ly/4dmbfLY #EADVCongress #RevolutionizingImmunology